23rd February 2007 - Antitope Ltd., announced a research agreement with the Dana Farber Cancer Institute, Inc. (“Dana-Farber”) for the generation of novel biologics for the potential treatment of cancer and infectious disease. As part of the agreement, Antitope will apply its proprietary Composite Human AntibodyTM technology to multiple targets identified by Dana-Farber to produce therapeutic antibodies with a reduced risk of immunogenicity.
